Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COTESARC
2024-510712-75-00Phase 2Authorised
- Sponsor
- Centre Léon Bérard
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab and cobimetinib in soft tissue sarcoma (STS), rhabdomyosarcoma (RMS) and malignant peripheral nerve sheath tumor (MPNST) (5 arms), sponsored by Centre Léon Bérard. Primary endpoints: Incidence of severe toxicities during the first cycle of treatment and Progression-free rate at 16 weeks. Planned start Dec 2024; status: authorised.
02
Drugs
atezolizumabcobimetinib
03
Conditions
soft tissue sarcoma (STS)rhabdomyosarcoma (RMS)malignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on 2024-510712-75-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510712-75-00.